HomeDIVISLAB • NSE
add
Divi's Laboratories Ltd
Previous close
₹5,977.10
Day range
₹5,980.00 - ₹6,056.95
Year range
₹3,350.00 - ₹6,275.85
Market cap
1.59T INR
Avg Volume
499.58K
P/E ratio
86.78
Dividend yield
0.50%
Primary exchange
NSE
In the news
Financials
Income Statement
Revenue
Net income
| (INR) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 23.38B | 22.47% |
Operating expense | 7.52B | 5.17% |
Net income | 5.10B | 46.55% |
Net profit margin | 21.81 | 19.64% |
Earnings per share | 19.51 | 48.82% |
EBITDA | 7.15B | 49.58% |
Effective tax rate | 29.36% | — |
Balance Sheet
Total assets
Total liabilities
| (INR) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 36.02B | -0.25% |
Total assets | 155.86B | 9.12% |
Total liabilities | 18.69B | 16.38% |
Total equity | 137.17B | — |
Shares outstanding | 265.62M | — |
Price to book | 11.57 | — |
Return on assets | — | — |
Return on capital | 11.30% | — |
Cash Flow
Net change in cash
| (INR) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 5.10B | 46.55% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Divi's Laboratories Limited is an Indian multinational pharmaceutical company and producer of active pharmaceutical ingredients and intermediates, headquartered in Hyderabad. The company manufactures and custom synthesizes generic APIs, intermediates. The company also manufactures and supplies nutraceutical ingredients through its subsidiary, Divi's Nutraceuticals. Divi's Laboratories is India's fourth largest publicly listed pharmaceutical company by market capitalization.
In October 2024, Divi and his family were ranked 29th on Forbes list of India’s 100 richest tycoons, with a net worth of $9.2 billion. Wikipedia
Founded
Oct 12, 1990
Website
Employees
9,741
